help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clapp, C.
Right arrow Articles by Weiner, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clapp, C.
Right arrow Articles by Weiner, R. I.

Endocrinology, Vol 133, 1292-1299, Copyright © 1993 by Endocrine Society

ARTICLES

The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis

C Clapp, JA Martial, RC Guzman, F Rentier-Delure and RI Weiner
Reproductive Endocrinology Center, University of California, San Francisco 94143.

The formation of a new blood supply, angiogenesis, is an essential component of carcinogenesis and unrestricted tumor growth. A substance capable of inhibiting angiogenesis would be of considerable therapeutic potential in the treatment of cancer. We previously reported that the 16-kilodalton N-terminal fragment of rat PRL (16K rPRL) was a potent inhibitor of capillary endothelial cell proliferation via a novel receptor. We now report that the nanomolar concentrations of recombinant human 16K PRL inhibit basal and basic fibroblast growth factor- or vascular endothelial growth factor-stimulated growth of bovine brain capillary endothelial cells. 16K human (h) PRL also inhibits stimulation of human umbilical vein endothelial cell proliferation by basic fibroblast growth factor. The organization of endothelial cells into capillary-like structures in type I collagen gels is also prevented by 16K hPRL. Furthermore, in an in vivo assay, the chick embryo chorioallantoic membrane assay, 16K hPRL as well as 16K rPRL were potent inhibitors of capillary formation. 16K hPRL, like 16K rPRL, maintains its biological activity as a partial PRL agonist at PRL receptors on mammary gland epithelial cells. These data demonstrate for the first time that the biological activity of 16K rPRL is not unique and that similar fragments of hPRL are active. The antiangiogenic activity of these molecules is conserved across avian and mammalian species. That 16K hPRL is a potent antiangiogenic factor in in vitro and an in vivo assay raises the exciting potential of this peptide being capable of inhibiting tumor growth.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Leanos-Miranda, J. Marquez-Acosta, G. M. Cardenas-Mondragon, Z. L. Chinolla-Arellano, R. Rivera-Leanos, S. Bermejo-Huerta, J. F. Romero-Arauz, G. Alvarez-Jimenez, J. C. Ramos-Leon, and A. Ulloa-Aguirre
Urinary Prolactin as a Reliable Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Pregnancy Outcomes
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2492 - 2499.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee
What Can We Learn from Rodents about Prolactin in Humans?
Endocr. Rev., February 1, 2008; 29(1): 1 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee
16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway
Cancer Res., November 15, 2007; 67(22): 11045 - 11053.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Ge, C. A. Fernandez, M. A. Moses, and D. S. Greenspan
Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor
PNAS, June 12, 2007; 104(24): 10010 - 10015.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. Piwnica, I. Fernandez, N. Binart, P. Touraine, P. A. Kelly, and V. Goffin
A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D
Mol. Endocrinol., December 1, 2006; 20(12): 3263 - 3278.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N.-Q.-N. Nguyen, S. P. Tabruyn, L. Lins, M. Lion, A. M. Cornet, F. Lair, F. Rentier-Delrue, R. Brasseur, J. A. Martial, and I. Struman
Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis
PNAS, September 26, 2006; 103(39): 14319 - 14324.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp
Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin
J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Shibuya, K. Watanabe, H. Yamashita, K. Shimizu, H. Miyashita, M. Abe, T. Moriya, H. Ohta, H. Sonoda, T. Shimosegawa, et al.
Isolation and Characterization of Vasohibin-2 as a Homologue of VEGF-Inducible Endothelium-Derived Angiogenesis Inhibitor Vasohibin
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1051 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E. Ueda, U. Ozerdem, Y.-H. Chen, M. Yao, K. T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A. M Walker
A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 95 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-h. Lee, M. Nishino, T. Mazumdar, G. E. Garcia, M. Galfione, F. L. Lee, C. L. Lee, A. Liang, J. Kim, L. Feng, et al.
16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway
Cancer Res., September 1, 2005; 65(17): 7984 - 7992.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. Aranda, J. C. Rivera, M. C. Jeziorski, J. Riesgo-Escovar, G. Nava, F. Lopez-Barrera, H. Quiroz-Mercado, P. Berger, G. Martinez de la Escalera, and C. Clapp
Prolactins Are Natural Inhibitors of Angiogenesis in the Retina
Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2947 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
K Horiguchi, S Yagi, K Ono, Y Nishiura, M Tanaka, M Ishida, and T Harigaya
Prolactin gene expression in mouse spleen helper T cells
J. Endocrinol., December 1, 2004; 183(3): 639 - 646.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Gonzalez, A. M. Corbacho, J. P. Eiserich, C. Garcia, F. Lopez-Barrera, V. Morales-Tlalpan, A. Barajas-Espinosa, M. Diaz-Munoz, R. Rubio, S.-H. Lin, et al.
16K-Prolactin Inhibits Activation of Endothelial Nitric Oxide Synthase, Intracellular Calcium Mobilization, and Endothelium-Dependent Vasorelaxation
Endocrinology, December 1, 2004; 145(12): 5714 - 5722.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. Lkhider, R. Castino, E. Bouguyon, C. Isidoro, and M. Ollivier-Bousquet
Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions
J. Cell Sci., October 1, 2004; 117(21): 5155 - 5164.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. Piwnica, P. Touraine, I. Struman, S. Tabruyn, G. Bolbach, C. Clapp, J. A. Martial, P. A. Kelly, and V. Goffin
Cathepsin D Processes Human Prolactin into Multiple 16K-Like N-Terminal Fragments: Study of Their Antiangiogenic Properties and Physiological Relevance
Mol. Endocrinol., October 1, 2004; 18(10): 2522 - 2542.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Z. Duenas, J. C. Rivera, H. Quiroz-Mercado, J. Aranda, Y. Macotela, P. M. de Oca, F. Lopez-Barrera, G. Nava, J. L. Guerrero, A. Suarez, et al.
Prolactin in Eyes of Patients with Retinopathy of Prematurity: Implications for Vascular Regression
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Pan, N.-Q.-N. Nguyen, H. Yoshida, F. Bentzien, L. C. Shaw, F. Rentier-Delrue, J. A. Martial, R. Weiner, I. Struman, and M. B. Grant
Molecular Targeting of Antiangiogenic Factor 16K hPRL Inhibits Oxygen-Induced Retinopathy in Mice
Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2413 - 2419.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. S. ROGERS, R. M. ROHAN, A. E. BIRSNER, and R. J. D'AMATO
Genetic loci that control the angiogenic response to basic fibroblast growth factor
FASEB J, July 1, 2004; 18(10): 1050 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A E Koch
Angiogenesis as a target in rheumatoid arthritis
Ann Rheum Dis, November 1, 2003; 62(90002): ii60 - 67.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. I. Kim, K. S. Kim, H. S. Kim, D. S. Kim, Y. Jang, K. H. Chung, and Y. S. Park
Inhibitory Effect of the Salmosin Gene Transferred by Cationic Liposomes on the Progression of B16BL6 Tumors
Cancer Res., October 1, 2003; 63(19): 6458 - 6462.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Musicki, G. J. Pepe, and E. D. Albrecht
Functional Differentiation of the Placental Syncytiotrophoblast: Effect of Estrogen on Chorionic Somatomammotropin Expression during Early Primate Pregnancy
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4316 - 4323.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. P. Tabruyn, C. M. Sorlet, F. Rentier-Delrue, V. Bours, R. I. Weiner, J. A. Martial, and I. Struman
The Antiangiogenic Factor 16K Human Prolactin Induces Caspase-Dependent Apoptosis by a Mechanism that Requires Activation of Nuclear Factor-{kappa}B
Mol. Endocrinol., September 1, 2003; 17(9): 1815 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler
The Role of Prolactin in Mammary Carcinoma
Endocr. Rev., February 1, 2003; 24(1): 1 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin
Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer
Cancer Res., January 15, 2003; 63(2): 386 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
E S Bamberger and C W Perrett
Angiogenesis in epithelian ovarian cancer
Mol. Pathol., December 1, 2002; 55(6): 348 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Volpert, W. Luo, T.-J. Liu, V. T. Estrera, C. Logothetis, and S.-H. Lin
Inhibition of Prostate Tumor Angiogenesis by the Tumor Suppressor CEACAM1
J. Biol. Chem., September 13, 2002; 277(38): 35696 - 35702.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Tarui, L. A. Miles, and Y. Takada
Specific Interaction of Angiostatin with Integrin alpha vbeta 3 in Endothelial Cells
J. Biol. Chem., October 19, 2001; 276(43): 39562 - 39568.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Bentzien, I. Struman, J.-F. Martini, J. Martial, and R. Weiner
Expression of the Antiangiogenic Factor 16K hPRL in Human HCT116 Colon Cancer Cells Inhibits Tumor Growth in Rag1-/- Mice
Cancer Res., October 1, 2001; 61(19): 7356 - 7362.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Dueñas, G. Nava, G. M. de la Escalera, and C. Clapp
Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells
Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
K. Camphausen, M. A. Moses, W.-D. Beecken, M. K. Khan, J. Folkman, and M. S. O’Reilly
Radiation Therapy to a Primary Tumor Accelerates Metastatic Growth in Mice
Cancer Res., March 1, 2001; 61(5): 2207 - 2211.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
J.-C. ZHANG, K. CLAFFEY, R. SAKTHIVEL, Z. DARZYNKIEWICZ, D. E. SHAW, J. LEAL, Y.-C. WANG, F.-M. LU, and K. R. MCCRAE
Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5
FASEB J, December 1, 2000; 14(15): 2589 - 2600.
[Abstract] [Full Text]

Home page
 Ann Rheum DisHome page
A. E. Koch
The role of angiogenesis in rheumatoid arthritis: recent developments
Ann Rheum Dis, November 1, 2000; 59(90001): i65 - 71.
[Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J.-F. Martini, C. Piot, L. M. Humeau, I. Struman, J. A. Martial, and R. I. Weiner
The Antiangiogenic Factor 16K PRL Induces Programmed Cell Death in Endothelial Cells by Caspase Activation
Mol. Endocrinol., October 1, 2000; 14(10): 1536 - 1549.
[Abstract] [Full Text]

Home page
 Physiol. Rev.Home page
M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy
Prolactin: Structure, Function, and Regulation of Secretion
Physiol Rev, October 1, 2000; 80(4): 1523 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Binart, C. Helloco, C. J. Ormandy, J. Barra, P. Clement-Lacroix, N. Baran, and P. A. Kelly
Rescue of Preimplantatory Egg Development and Embryo Implantation in Prolactin Receptor-Deficient Mice after Progesterone Administration
Endocrinology, July 1, 2000; 141(7): 2691 - 2697.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Halloran, W. W. Carley, P. J. Polverini, C. J. Haskell, S. Phan, B. J. Anderson, J. M. Woods, P. L. Campbell, M. V. Volin, A. E. Backer, et al.
Ley/H: An Endothelial-Selective, Cytokine-Inducible, Angiogenic Mediator
J. Immunol., May 1, 2000; 164(9): 4868 - 4877.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. M. Corbacho, G. Nava, J. P. Eiserich, G. Noris, Y. Macotela, I. Struman, G. Martinez de la Escalera, B. A. Freeman, and C. Clapp
Proteolytic Cleavage Confers Nitric Oxide Synthase Inducing Activity upon Prolactin
J. Biol. Chem., April 28, 2000; 275(18): 13183 - 13186.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Rosen
Antiangiogenic Strategies and Agents in Clinical Trials
Oncologist, April 1, 2000; 5(90001): 20 - 27.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. E. Turner, Z. Nagy, K. C. Gatter, M. M. Esiri, A. L. Harris, and J. A. H. Wass
Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1159 - 1162.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
R. S. Kerbel
Tumor angiogenesis: past, present and the near future
Carcinogenesis, March 1, 2000; 21(3): 505 - 515.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. S. O'Reilly, D. Wiederschain, W. G. Stetler-Stevenson, J. Folkman, and M. A. Moses
Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance
J. Biol. Chem., October 8, 1999; 274(41): 29568 - 29571.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Z. Duenas, L. Torner, A. M. Corbacho, A. Ochoa, G. Gutierrez-Ospina, F. Lopez-Barrera, F. A. Barrios, P. Berger, Gonzalo Martinez de la Escalera, and C. Carmen
Inhibition of Rat Corneal Angiogenesis by 16-kDa Prolactin and by Endogenous Prolactin-like Molecules
Invest. Ophthalmol. Vis. Sci., October 1, 1999; 40(11): 2498 - 2505.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. MIOSGE, T. SASAKI, and R. TIMPL
Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls
FASEB J, October 1, 1999; 13(13): 1743 - 1750.
[Abstract] [Full Text]

Home page
 BloodHome page
S. E. Pike, L. Yao, J. Setsuda, K. D. Jones, B. Cherney, E. Appella, K. Sakaguchi, H. Nakhasi, C. D. Atreya, J. Teruya-Feldstein, et al.
Calreticulin and Calreticulin Fragments Are Endothelial Cell Inhibitors That Suppress Tumor Growth
Blood, October 1, 1999; 94(7): 2461 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Khurana, K. Liby, A. R. Buckley, and N. Ben-Jonathan
Proteolysis of Human Prolactin: Resistance to Cathepsin D and Formation of a Nonangiostatic, C-Terminal 16K Fragment by Thrombin
Endocrinology, September 1, 1999; 140(9): 4127 - 4132.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. J. Woods, C. F. Kemp, J. David, I. G. Sumner, and P. J. Lowry
Cleavage of Recombinant Human Corticotropin-Releasing Factor (CRF)-Binding Protein Produces a 27-Kilodalton Fragment Capable of Binding CRF
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2788 - 2794.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
I.-C. Kang, Y.-D. Lee, and D.-S. Kim
A Novel Disintegrin Salmosin Inhibits Tumor Angiogenesis
Cancer Res., August 1, 1999; 59(15): 3754 - 3760.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Cao, H.-L. Wu, N. Veitonmaki, P. Linden, J. Farnebo, G.-Y. Shi, and Y. Cao
Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
PNAS, May 11, 1999; 96(10): 5728 - 5733.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. D’Angelo, J.-F. Martini, T. Iiri, W. J. Fantl, J. Martial, and R. I. Weiner
16K Human Prolactin Inhibits Vascular Endothelial Growth Factor-Induced Activation of Ras in Capillary Endothelial Cells
Mol. Endocrinol., May 1, 1999; 13(5): 692 - 704.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
S. E. Hankinson, W. C. Willett, D. S. Michaud, J. E. Manson, G. A. Colditz, C. Longcope, B. Rosner, and F. E. Speizer
Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women
J Natl Cancer Inst, April 7, 1999; 91(7): 629 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Struman, F. Bentzien, H. Lee, V. Mainfroid, G. D'Angelo, V. Goffin, R. I. Weiner, and J. A. Martial
Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis
PNAS, February 16, 1999; 96(4): 1246 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
H. Gerber, K. Hillan, A. Ryan, J Kowalski, G. Keller, L Rangell, B. Wright, F Radtke, M Aguet, and N Ferrara
VEGF is required for growth and survival in neonatal mice
Development, January 3, 1999; 126(6): 1149 - 1159.
[Abstract] [PDF]

Home page
 JEMHome page
S. E. Pike, L. Yao, K. D. Jones, B. Cherney, E. Appella, K. Sakaguchi, H. Nakhasi, J. Teruya-Feldstein, P. Wirth, G. Gupta, et al.
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth
J. Exp. Med., December 21, 1998; 188(12): 2349 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Lee, I. Struman, C. Clapp, J. Martial, and R. I. Weiner
Inhibition of Urokinase Activity by the Antiangiogenic Factor 16K Prolactin: Activation of Plasminogen Activator Inhibitor 1 Expression
Endocrinology, September 1, 1998; 139(9): 3696 - 3703.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Griscelli, H. Li, A. Bennaceur-Griscelli, J. Soria, P. Opolon, C. Soria, M. Perricaudet, P. Yeh, and H. Lu
Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
PNAS, May 26, 1998; 95(11): 6367 - 6372.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. L. Jones, H. O. D. Critchley, J. Brooks, H. N. Jabbour, and A. S. McNeilly
Localization and Temporal Expression of Prolactin Receptor in Human Endometrium
J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 258 - 262.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. Soker, S. Gollamudi-Payne, H. Fidder, H. Charmahelli, and M. Klagsbrun
Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF165
J. Biol. Chem., December 12, 1997; 272(50): 31582 - 31588.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Reynolds, K. T. Montone, C. M. Powell, J. E. Tomaszewski, and C. V. Clevenger
Expression of Prolactin and Its Receptor in Human Breast Carcinoma
Endocrinology, December 1, 1997; 138(12): 5555 - 5560.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Gately, P. Twardowski, M. S. Stack, D. L. Cundiff, D. Grella, F. J. Castellino, J. Enghild, H. C. Kwaan, F. Lee, R. A. Kramer, et al.
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
PNAS, September 30, 1997; 94(20): 10868 - 10872.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Cao, A. Chen, S. S. A. An, R.-W. Ji, D. Davidson, Y. Cao, and M. Llinas
Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth
J. Biol. Chem., September 5, 1997; 272(36): 22924 - 22928.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. J. Woods, C. F. Kemp, J. David, and P. J. Lowry
Heterogeneity of the Human Corticotropin-Releasing Factor-Binding Protein
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1566 - 1571. <